What are Alnylam Pharmaceuticals's total assets?

Alnylam Pharmaceuticals (ALNY) holds $5.1B in total assets, up 21.7% year over year.

How much debt does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals carries $263.7M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.25.

How much cash does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals holds $1.7B in cash and equivalents.

Can Alnylam Pharmaceuticals cover its short-term obligations?

Its current ratio is 3.13 — current assets exceed current liabilities.

Where does Alnylam Pharmaceuticals's balance sheet data come from?

Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alnylam Pharmaceuticals ALNY Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$1.66B+71.2%	$968.65M+18.9%	$814.88M-6.2%	$868.56M+5.6%
Short-term investments	$1.25B-27.3%	$1.72B+6.5%	$1.62B+24.5%	$1.3B-16.2%
Restricted cash	——	——	——	——
Accounts receivable, net	$777.57M+91.8%	$405.31M+23.6%	$327.79M+37.7%	$237.96M+19.8%
Inventories	$82.72M+5.4%	$78.51M-11.9%	$89.15M-30.9%	$128.96M+49.3%
Raw materials	$14.18M-40.8%	$23.97M+2.7%	$23.35M+4.6%	$22.32M+51.2%
Work in process	$65.12M+0.2%	$64.98M-15.6%	$76.96M-32.4%	$113.78M+12.7%
Finished goods	$32.34M+22.3%	$26.43M+5.2%	$25.12M-1.9%	$25.61M+266%
Prepaid expenses and other current assets	$281.89M+141%	$116.96M-7.5%	$126.38M-4.9%	$132.92M+50.9%
Total current assets	$4.05B+22.9%	$3.3B+10.5%	$2.98B+10.8%	$2.69B-4.1%
Property and equipment, net	$513.15M+2.1%	$502.78M-4.4%	$526.06M+0.5%	$523.49M+4.3%
Operating lease right-of-use assets	$194.92M+2.0%	$191.15M-4.3%	$199.73M-7.2%	$215.14M-7.1%
Other non-current assets	$59.46M-9.0%	$65.31M+5.5%	$61.9M-6.3%	$66.09M+9.8%
Total assets	$4.97B+17.1%	$4.24B+10.7%	$3.83B+8.0%	$3.55B-2.7%
Accrued expenses	$1.08B+36.1%	$793.69M+11.3%	$713.01M+30.7%	$545.46M+38.0%
Deferred revenue	$4.85M-91.3%	$55.48M-46.0%	$102.75M+144%	$42.11M-71.8%
Operating lease liabilities, current	$45.52M+8.7%	$41.89M+0.9%	$41.51M-1.1%	$41.97M+3.5%
Total current liabilities	$1.47B+23.6%	$1.19B+22.6%	$967.79M+26.0%	$767.92M+10.4%
Operating lease liabilities, non-current	$225.09M-1.9%	$229.54M-5.6%	$243.1M-7.0%	$261.34M-7.1%
Other non-current liabilities	$7.59M+52.8%	$4.97M-98.4%	$308.44M+45.1%	$212.58M+115%
Total liabilities	$4.18B+0.1%	$4.17B+3.0%	$4.05B+9.3%	$3.7B+21.3%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	250M+19,235%	1.3M+2.7%	1.3M+1.5%	1.2M+3.2%
Additional paid-in capital	$7.51B+1.7%	$7.39B+8.5%	$6.81B+5.5%	$6.45B+6.5%
Retained earnings	-$6.7B+8.0%	-$7.29B-4.0%	-$7.01B-6.7%	-$6.57B-20.8%
Accumulated other comprehensive income (loss)	-$20.1M+41.8%	-$34.52M-47.7%	-$23.38M+47.7%	-$44.65M-34.3%
Total stockholders' equity	$789.18M+1,076%	$67.09M+130%	-$220.64M-39.5%	-$158.22M-127%
Total liabilities and stockholders' equity	$4.97B+17.1%	$4.24B+10.7%	$3.83B+8.0%	$3.55B-2.7%
Available For Sale Securities Debt Securities Current	$1.25B-27.3%	$1.72B+6.5%	$1.62B+24.5%	$1.3B-16.2%
Deferred Tax Assets and Other Non-Current Assets	$59.46M-9.0%	$65.31M+5.5%	$61.9M-6.3%	$66.09M+9.8%
Net Investment in Lease	$194.92M+2.0%	$191.15M-4.3%	$199.73M-7.2%	$215.14M-7.1%
Deferred tax assets	$125.98M+7.8%	$116.86M+1,057%	$10.1M—	——
Operating lease right-of-use assets	$194.92M+2.0%	$191.15M-4.3%	$199.73M-7.2%	$215.14M-7.1%
Other non-current assets	$59.46M-9.0%	$65.31M+5.5%	$61.9M-6.3%	$66.09M+9.8%
Operating Lease Right-of-Use Assets in Other Assets	$194.92M+2.0%	$191.15M-4.3%	$199.73M-7.2%	$215.14M-7.1%
Software and Technology Licenses, Net	$59.46M-9.0%	$65.31M+5.5%	$61.9M-6.3%	$66.09M+9.8%
Accrued Contingent Liabilities	$0—	$0—	——	——
Other Commercial Liabilities	$1.08B+36.1%	$793.69M+11.3%	$713.01M+30.7%	$545.46M+38.0%
Accrued Liabilities, Current	$1.08B+36.1%	$793.69M+11.3%	$713.01M+30.7%	$545.46M+38.0%
Liabilities related to the sale of future royalties and development funding	$220.07M+94.7%	$113.02M—	——	——
Convertible Debt (Non-Current)	$1.01B-1.6%	$1.02B+0.4%	$1.02B+0.4%	$1.02B—
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	132.4M+2.4%	129.3M+2.8%	125.8M+1.5%	123.9M+3.1%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Additional paid-in capital	$7.51B+1.7%	$7.39B+8.5%	$6.81B+5.5%	$6.45B+6.5%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1.32M+2.4%	$1.29M+2.7%	$1.26M+1.5%	$1.24M+3.2%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$250M0.0%	$250M0.0%	$250M0.0%	$250M0.0%
Common stock, shares issued (in shares)	$132.38M+2.4%	$129.29M+2.8%	$125.79M+1.5%	$123.93M+3.1%
Common Stock, Shares, Outstanding	$132.38M+2.4%	$129.29M+2.8%	$125.79M+1.5%	$123.93M+3.1%
Convertible debentures	$1.01B-1.6%	$1.02B+0.4%	$1.02B+0.4%	$1.02B—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents	$88K—	——	——	——
Gross Unrealized Gains	$3.45M—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents	$1.27B—	——	——	——
Fair Value	$1.27B—	——	——	——
Inventory, Current And Noncurrent	$111.64M-3.2%	$115.38M-8.0%	$125.43M-22.4%	$161.7M+31.8%
Raw materials	$14.18M-40.8%	$23.97M+2.7%	$23.35M+4.6%	$22.32M+51.2%
Loss Contingency Accrual	$0—	$0—	——	——
Number of commercialized products	——	——	——	——
Number of partnered products	——	——	——	——
Number of marketed products	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Restricted Investments, Noncurrent	$22.17M-67.7%	$68.59M+38.9%	$49.39M0.0%	$49.39M+20.8%
Liabilities related to the sale of future royalties and development funding, net of current portion	$1.47B+10.2%	$1.33B—	——	——
Valuation Allowances And Reserves Balance	$425.65M+17.6%	$361.82M—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Alnylam Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Alnylam Pharmaceuticals's total assets?: Alnylam Pharmaceuticals (ALNY) holds $5.1B in total assets, up 21.7% year over year.
How much debt does Alnylam Pharmaceuticals have?: Alnylam Pharmaceuticals carries $263.7M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.25.
How much cash does Alnylam Pharmaceuticals have?: Alnylam Pharmaceuticals holds $1.7B in cash and equivalents.
Can Alnylam Pharmaceuticals cover its short-term obligations?: Its current ratio is 3.13 — current assets exceed current liabilities.
Where does Alnylam Pharmaceuticals's balance sheet data come from?: Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.